Drug induced vitiligo-like depigmentation from a CDK 4/6 inhibitor
On B Chan, John C Su, Anousha Yazdabadi, Arlene Chan
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | WILEY | Published : 2021
Ribociclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK 4/6) that is used in combination with an aromatase inhibitor in the first-line setting for advanced or metastatic hormone receptor positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. We report two cases of drug-induced vitiligo-like depigmentation (DI-VLD) associated with ribociclib. The awareness of this side effect is important given the increasing use of this drug and others with a similar mechanism of action.